Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Blum

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphomaAmy L Hoerr, Feng Gao, Josephine Hidalgo, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
British Journal of Haematology|February 26, 2013
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adultsChristine L Phillips, Stella M Davies, Richard McMasters, et al.
Cancer|April 16, 2017
Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemiaHanna J Khoury, Robert H Collins, William Blum, et al.
Blood|February 27, 2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
Leukemia & Lymphoma|December 22, 2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca Klisovic, Jeffrey S Johnston, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemiaRebecca B Klisovic, William Blum, Xiaohui Wei, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|August 29, 2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantGalena Salem, Amy S Ruppert, Patrick Elder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphomaAmy L Hoerr, Feng Gao, Josephine Hidalgo, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
British Journal of Haematology|February 26, 2013
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adultsChristine L Phillips, Stella M Davies, Richard McMasters, et al.
Cancer|April 16, 2017
Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemiaHanna J Khoury, Robert H Collins, William Blum, et al.
Blood|February 27, 2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
Leukemia & Lymphoma|December 22, 2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca Klisovic, Jeffrey S Johnston, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemiaRebecca B Klisovic, William Blum, Xiaohui Wei, et al.
Pageof 12